Fresh analysis suggests that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who end conventional diet and exercise programs.
Findings released in a major medical journal shows that while obese individuals frequently drop substantial amounts of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month once they quit.
"Users using such medications should be informed of the risk of quick rebound weight gain when the treatment ends," warns lead investigator Dr. Susan Jebb.
This pace of regain suggests a return to original weight in about a year and a half.
Analyzing Approaches
The study, which looked at dozens of trials involving thousands of patients, contrasted the results of these new drugs with conventional dieting.
The team emphasize that people who lose weight through diet and exercise typically have a more gradual creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Quick Regain
Doctors believe the way of the drugs explains the accelerated rebound.
The injections copy a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of the hormone concentrations several times higher than normal may cause the system to produce less of its endogenous hormone, and may also reduce responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' means hunger is no longer kept in check, making overeating far more likely."
A Lifelong Condition?
Medical guidelines suggest the injections for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians contend that, considering the high risk of weight regain, the treatment might need to be long-term.
This view is supported by drug manufacturers, who note that the findings "underscore the long-term nature of excess weight," comparing it to managing diseases like diabetes.
User Testimonies
Individuals who have stopped the medication explain a sudden resurgence of appetite.
"I experienced a switch that goes on and you become starving," said a patient.
The struggle is compounded if patients have not established sustainable lifestyle or habit changes during treatment.
Growing Interest
Survey data show that millions of adults in the UK have tried these injections in the past year, with desire being substantial.
- Use is higher among females compared to males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, experts caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic solution and maintained weight loss relies on combined behavioural support.
